Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action

Mark J. Millan

Abstract: Generalized anxiety disorder (GAD), the most frequently diagnosed form of anxiety, is usually treated by cognitive-behavioural approaches or medication; in particular, benzodiazepines (acutely) and serotonin or serotonin/noradrenaline reuptake inhibitors (long term). Efficacy, compliance, and acceptability are, however, far from ideal, reinforcing interest in alternative options. Agomelatine, clinically employed in the treatment of major depression, expresses anxiolytic properties in rodents and was effective in the treatment of GAD (including severely ill patients) in several double-blind, short-term (12 weeks) and relapse-prevention (6 months) studies. At active doses, the incidence of adverse effects was no higher than for placebo. Agomelatine possesses a unique binding profile, behaving as a melatonin [MT\textsubscript{1}/MT\textsubscript{2}] receptor agonist and 5-HT\textsubscript{2C} receptor antagonist, yet recognizing neither monoamine transporters nor GABA\textsubscript{A} receptors. Extensive evidence supports a role for 5-HT\textsubscript{2C} receptors in the induction of anxious states, and their blockade likely plays a primary role in mediating the anxiolytic actions of agomelatine, including populations in the amygdala and bed nucleus of stria terminalis, as well as the hippocampus. Recruitment of MT receptors in the suprachiasmatic nucleus, thalamic reticular nucleus, and hippocampus appears to fulfil a complimentary role. Downstream of 5-HT\textsubscript{2C} and MT receptors, modulation of stress-sensitive glutamatergic circuits and altered release of the anxiogenic neuropeptides, corticotrophin-releasing factor, and vasoressin, may be implicated in the actions of agomelatine. To summarize, agomelatine exerts its anxiolytic actions by mechanisms clearly distinct from those of other agents currently employed for the management of GAD.

Plain Language Summary

How agomelatine helps in the treatment of anxiety disorders

Introduction:
- Anxiety disorders have a significant negative impact on quality of life.
- The most common type of anxiety disorder, called generalized anxiety disorder (GAD), is associated with nervousness and excessive worry.
- These symptoms can lead to additional symptoms like tiredness, sleeplessness, irritability, and poor attention.
- GAD is generally treated through either cognitive-behavioural therapy or medication. However, widely used drugs like benzodiazepines and serotonin reuptake inhibitors have adverse effects.
- Agomelatine, a well-established antidepressant drug, has shown anxiety-lowering (‘anxiolytic’) properties in rats and has been shown to effectively treat GAD with minimal side effects.
• However, exactly how it acts on the brain to manage GAD is not yet clear.
• Thus, this review aims to shed light on agomelatine’s mechanism of action in treating GAD.

**Methods:**
• The authors reviewed studies on how agomelatine treats anxiety in animals.
• They also looked at clinical studies on the effects of agomelatine in people with GAD.

**Results:**
• The study showed that agomelatine ‘blocks’ a receptor in nerve cells, which plays a role in causing anxiety, called the 5-HT\textsubscript{2C} receptor.
• Blocking this receptor, especially in specific brain regions such as nerve cells of the amygdala, bed nucleus of stria terminalis, and hippocampus, produced the anxiety reduction seen during agomelatine treatment.
• Agomelatine also activates the melatonin (MT) receptor, which is known to keep anxiety in check, promote sleep, and maintain the sleep cycle.
• Agomelatine should thus tackle sleep disturbances commonly seen in patients with GAD.
• Beyond 5-HT\textsubscript{2C} and MT receptors, signalling molecules in nerve cells that are known to be involved in anxiety disorders (called ‘neurotransmitters’ and ‘neuropeptides’) are also affected by agomelatine.

**Conclusion:**
• Agomelatine’s anxiolytic effects are caused by mechanisms that are distinct from those of other medications currently used to treat GAD.
• This explains its therapeutic success and minimal adverse side effects.

**Keywords:** 5-HT\textsubscript{2C} receptor, fear, GABA, glutamate, melatonin receptor, stress

Received: 12 January 2022; revised manuscript accepted: 4 March 2022.
Introduction: core features of GAD and its current treatment

Anxiety disorders are a diverse assemblage of conditions that have a serious and negative impact on quality of life. When diagnosed in children, adolescents, and young adults, they often persist into later life. The most common class of anxiety disorder is GAD, which unfortunately is becoming more prominent amid the current COVID pandemic. Generalized anxiety disorder (GAD) is typically characterized by pervasive anxiety and nervousness, disproportionate worry, and overgeneralization of genuine fear to neutral or ambivalent stimuli, sometimes on the basis of previous adverse experiences. Distressing emotions and thoughts are difficult to control, persist over months, and are associated with symptoms like fatigue, insomnia, irritability, poor concentration, attentional deficits, and physical complaints. Accordingly, GAD disrupts social and familial relationships and interferes with work and daily activities. Furthermore, GAD is frequently comorbid with other anxious states like social phobia and also with dysthymia or frank depression.

Among a range of potential therapies, benzodiazepines are usually reserved for the immediate and acute (hours to days) control of GAD owing to the risk of dependence and a withdrawal syndrome, in addition to sedation and impairment of cognition. First-line and long-term treatment is mainly oriented around cognitive-behavioural and relaxation techniques, as well as the administration of selective...
serotonin reuptake inhibitors (SSRIs) and serotonin/noradrenaline reuptake inhibitors (SNRIs).\(^2,8–14\) In certain (rare) cases, the 5-HT\(_{1A}\) partial agonist, buspirone, is prescribed.\(^2,14\) Furthermore, the antiepileptic/analgesic and gabapentoid, pregabalin, may sometimes be administered. However – especially in association with recreational drugs and in patients with substance-abuse disorders – it presents a risk of misuse and addiction, while potential, ion channel-mediated toxic actions should also not be neglected.\(^15–17\) Where treatment-resistance or intolerance is encountered with standard medication, other agents may be considered such as the antidepressants, imipramine, mirtazapine, and trazodone, and (usually as adjuncts and in low doses) second-generation antipsychotics like olanzapine and quetiapine.\(^13,18\)

A broad range of agents acting via contrasting molecular substrates is, then, available for the control of GAD. However, they all possess disadvantages in terms of incomplete efficacy, irresponsible patients and undesirable secondary actions. For example, some patients cannot tolerate SSRIs and SNRIs, and hence do not properly comply with their prescription. These limitations underlie continuing efforts to find improved – and mechanistically distinct – medication for the treatment of GAD.\(^2,11,19–21\)

The present article focusses on one such agent, agomelatine (Figure 1). In the wake of early studies documenting its anxiolytic properties in rodents, clinical studies have found that agomelatine is efficacious in the treatment of GAD. Agomelatine possesses a distinct binding profile/mode of action which can be related both to its therapeutic efficacy in GAD and to its comparatively good acceptability compared to other agents.

### Agomelatine as a novel and mechanistically distinct option for GAD

In 2009, agomelatine was launched in Europe for the treatment of major depressive episodes in adults, and it was progressively authorized for use in major depression across a suite of countries in Asia, Africa, Australasia, and South America. (At that time, the parent company Servier was not present in the United States: while now represented, the focus is on Oncology and Research). Agomelatine was the first antidepressant to be licenced that possesses a non-monoaminergic component of activity, its unique pharmacological profile comprising dual-antagonist properties at 5-HT\(_{2C}\) receptors as well as agonist properties at melatonin (MT\(_1\)) and MT\(_2\) receptors\(^22–25\) (see further below). This pattern of binding differs from all other classes of antidepressant currently in use, and it is distinct to the aforementioned agents clinically employed to treat GAD. Furthermore, by contrast to benzodiazepines, agomelatine does not interact with either ortho or allospheric sites on GABA\(_{A}\) receptors. In addition, agomelatine does not bind to the gabapentin-responsive alpha2delta subunit of voltage-dependent Ca\(^{2+}\) channels. In contrast to buspirone, it is devoid of affinity for 5-HT\(_{1A}\) receptors and, in distinction to SSRIs and SNRIs, agomelatine does not recognize monoamine reuptake sites.\(^22,23,25\)

### Table 1. Summary of studies exploring the respective roles of 5-HT\(_{2C}\) antagonist versus melatonin agonist properties in the anxiolytic actions of agomelatine in rodents.

<table>
<thead>
<tr>
<th>Model</th>
<th>Vogel conflict</th>
<th>Geller conflict</th>
<th>Social interaction</th>
<th>Social defeat</th>
<th>Plus maze</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agomelatine alone</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes/No</td>
</tr>
<tr>
<td>5-HT(_{2C}) antagonists</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Not tested</td>
<td>No</td>
</tr>
<tr>
<td>Melatonin alone</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes [partial]</td>
<td>Yes/No</td>
</tr>
<tr>
<td>MT antagonist vs. agomelatine</td>
<td>Not blocked</td>
<td>Not tested</td>
<td>Not blocked</td>
<td>Not tested</td>
<td>Blocked</td>
</tr>
</tbody>
</table>

MT, melatonin. Agomelatine was compared to several selective 5-HT\(_{2C}\) antagonists and/or to melatonin under identical conditions. The activity of agomelatine in the social defeat model was abolished by ablation of the MT\(_1\) receptor–rich suprachiasmatic nucleus. Variable results have been acquired with both agomelatine and melatonin in the elevated plus maze. In one study where agomelatine was effective, its actions were blunted by administration of the melatonin antagonist, S22153. This drug was likewise employed in interaction with agomelatine in the Vogel conflict and Social interaction procedures where it was, by contrast, inactive. For details, see main text.
The first indications that agomelatine might be of use for the management of GAD (and anxious states in general) emerged from experimental work in rodents.26 Potential therapeutic efficacy in GAD was subsequently assessed within the framework of controlled clinical trials over 2008 to 2018, and these observations constitute the basis for a dossier in preparation for submission to the appropriate Health Authorities.27,28 These observations are consecutively summarized below and then its potential mechanisms of action are considered in greater detail.

Anxiolytic properties of agomelatine: actions in animal models

In recent years, considerable efforts have been made to ameliorate the validity of animal models of anxiety, both for characterization of the underlying pathophysiology and for the improved detection of novel anxiolytics: in parallel, several ‘translational’ initiatives have been undertaken for the improved appraisal of potential anxiolytic activity in human subjects.29–38 Yet no specific animal model for GAD, a multidimensional and complex disorder, has to date been described.

On the contrary, an exaggerated response to fear is common in GAD patients3,6 suggesting that conditioned fear procedures in rats may have significant construct value for GAD. It is, thus, of note that agomelatine robustly reduced the freezing response to a conditioned aversive stimulus in rats.39 Agomelatine has also been evaluated in a suite of other paradigms mirroring diverse dimensions of anxious states. One example is a Vogel Conflict (approach-avoidance) procedure, whereby anxiolytic agents release a response for food or water suppressed by a mild punishment – independently of any potential influence upon appetite or nociceptive thresholds.40 Another example is provided by active Social Interaction with an unknown conspecific:26,41 this is of note because there is increasing interest in overlapping features and cellular substrates of GAD and social anxiety.42,43 In these and certain other procedures of potential anxiolytic properties, agomelatine displayed robust efficacy, though it has not invariably proven active in elevated plus maze and conditioned ultrasonic vocalization (USV) procedures23,24,26,41,44,45 (Table 1). Where active, the anxiolytic actions of agomelatine are expressed both acutely and upon sustained (several weeks) administration.22,23,26,44

Interestingly, agomelatine also counters anxiety-related behaviours in several rodent models of ‘depression’, including pre-natal or chronic stress.23,46,47 These observations, together with its clinically proven antidepressant properties,22 support the use of agomelatine for helping patients with mixed anxious-depressive states7,48 – a possibility yet to be formally addressed in dedicated clinical trials.

Anxiolytic properties of agomelatine: actions in clinical studies of GAD

In the wake of the encouraging experimental findings outlined above, clinical efficacy of agomelatine (25–50 mg/day) was evaluated in patients suffering from GAD. Efficacy versus placebo was demonstrated in three independent, double-blind, ‘short-term’ (12-week) studies that employed both the Hamilton Anxiety Scale as well as the Sheehan Disability Scale to monitor functional impairment.49–51 The positive outcome of these respective studies was recently reprised by a pooled meta-analysis that underpinned evidence for robust efficacy both in alleviating symptoms and in enhancing global patient function.27,28 Efficacy of agomelatine was comparable to the active control, escitalopram (an SSRI), and secondary analysis supported effectiveness in severe GAD (Hamilton Anxiety Scale > 21).28,49–52 Although its precise onset of efficacy remains to be further characterized, clinical studies suggest activity within the 1–3 weeks after commencing administration in at least some patients.28,49–52 A further study undertaken over 6 months demonstrated efficacy in preventing relapse.53

Despite concerns from depressed patients about a dose-dependent (albeit low) risk of hepatotoxicity that necessitates control of liver function,22,54 only a small percentage (1.8%) of patients in the short-term studies of GAD showed potentially significant increases in transaminases: there were no cases of liver disease and transaminase levels normalized after stopping administration in all patients. This issue obviously requires close future surveillance, but data in GAD are so far reassuring, and recent comparative analyses of agomelatine with other antidepressants in major depression reinforce this conclusion.55–57 Furthermore, tolerance was good in GAD patients with no difference in the frequency of discontinuation-related adverse effects in the agomelatine (headache, nasopharyngitis, and nausea) versus placebo groups (both 2.1%). In addition, there was no evidence for an agomelatine withdrawal syndrome in either the short-term or relapse-prevention studies.28,49–53 These observations are consistent with clinical observations
acquired in studies of its antidepressant properties. More specifically, they support the notion that the distinctive receptor-binding profile of agomelatine should not be associated with the risks of tolerance, dependence/withdrawal, and recreational abuse that burden benzodiazepines. Agomelatine lacks affinity for the 5-HT transporter and clinical work bears out the low risk of disrupted sexual function and sleep – or an acute exacerbation of anxiety – at the onset of treatment. This represents an important gain over SSRIs and SNRIs – and may also be an advantage compared with buspirone.

Activation of 5-HT$_{2C}$ receptors, for example, on hypothalamic proopiomelanocortin neurons, suppresses appetite. Conversely, 5-HT$_{2C}$ receptor blockade, in particular when coupled to histaminergic and/or muscarinic receptor antagonism, is a risk factor for increased food consumption, obesity, and metabolic dysregulation, as seen with numerous tricyclic antidepressants and ‘atypical’ antipsychotics like olanzapine. It is of note, then, that agomelatine does not recognize histaminergic, muscarinic, or other classes of receptor incriminated in triggering weight gain.

In addition, agomelatine is a neutral antagonist rather than inverse agonist at 5-HT$_{2C}$ receptors, so it does not decrease 5-HT$_{2C}$ receptor-mediated transmission to below ‘normal or default’ levels. These characteristics suggest that agomelatine has a low risk of metabolic perturbation and obesity, an assertion underscored by clinical observations in studies of both GAD and major depression. There is also a correspondingly low risk of rebound anxiety or a discontinuation syndrome at the end of treatment.

To recap, then, the distinctive 5-HT$_{2C}$ antagonist/MT agonist receptor-binding profile of agomelatine can be related both to its therapeutic efficacy in GAD and to its good tolerance. Its favourable clinical profile was recently underscored in two separate meta-analyses of a diversity of agents clinically evaluated for the treatment of GAD. Nonetheless, for a more fine-grained and complete understanding of the mechanisms of action of agomelatine in the control of GAD, it is instructive to consider a suite of observations acquired mainly in rodents.

**Key role for 5-HT$_{2C}$ receptors in the anxiolytic actions of agomelatine: supporting studies in rodents and humans**

In the light of the above-discussed evidence that 5-HT$_{2C}$ receptor antagonism participates in the anxiolytic actions of agomelatine, it is instructive to evoke studies undertaken in animals and in
humans that underpin a role for 5-HT$_{2C}$ receptor blockade in the relief of GAD and anxious states.

First, paralleling observations obtained in direct, side-by-side comparisons with agomelatine, diverse classes of 5-HT$_{2C}$ receptor antagonist exert anxiolytic properties across a range of animal models. Conversely, 5-HT$_{2C}$ receptor agonists generally display anxiogenic properties. Second, in line with these findings, 5-HT$_{2C}$ receptor knockout mice display an ‘anxious’ profile, though this is only seen under certain conditions and a tendency for increased locomotor activity complicates interpretation of data. Third, indirect, 5-HT-mediated activation of 5-HT$_{2C}$ receptors mediates the acute anxiogenic actions of SSRIs in rodents, notably in the social interaction procedure in which agomelatine include the habenula, the dorsal striatum and the periaqueductal grey (not shown, see main text). Agomelatine may also act at 5-HT$_{1}$ sites in the SCN (directly or via modulation of circadian rhythms) to affect anxious states, and via modulation of the secretion of vasopressin/oxytocin from paraventricular/supra-optic nuclei, likely downstream of 5-HT$_{2C}$ receptors. This figure represents a work in progress: further study is needed to more precisely determine the cellular and neural mechanisms of anxiolytic action of agomelatine in GAD.

Before moving on to MT receptors, it should be mentioned that agomelatine displays affinity comparable to that for 5-HT$_{2C}$ receptors at closely related 5-HT$_{2B}$ receptors: mCPP and ritanserin also interact with 5-HT$_{2B}$ receptors. In contrast...
to 5-HT$_{2C}$ receptors, however, there is no evidence from either pharmacological or gene knockout studies that 5-HT$_{2B}$ receptor activation elicits anxious states, nor that their inactivation is associated with anxiolytic properties. Indeed, as compared to 5-HT$_{2C}$ receptors, several studies have reported that 5-HT$_{2B}$ agonists rather than antagonists display anxiolytic actions.48,70,96,97 Accordingly, there is no evidence for a role of 5-HT$_{2B}$ blockade in the influence of agomelatine upon anxiety, and the discussion below focusses on 5-HT$_{2C}$ receptors.

A complementary role for MT receptors in the anxiolytic actions of agomelatine: supporting studies in rodents and humans

As regards a complementary role for melatonergic agonism in the anxiolytic actions of agomelatine, supporting data are less broad-based than those for 5-HT$_{2C}$ receptor blockade. Nonetheless, a few studies have reported anxiolytic actions of MT (as a function of the procedure and time of light cycle) in rodent models like the elevated plus maze and novelty suppressed feeding tests.41,98–103 Most pertinently, in a paradigm of social defeat, agomelatine abrogated associated anxiety-related behaviours, and its actions were partially reproduced by MT (5-HT$_{2C}$ antagonists were not unfortunately tested) and abolished by lesions of the MT$_1$ receptor–rich suprachiasmatic nucleus (SCN).45 Furthermore, increases in anxiety have been documented in MT$_1$ knock mice.104 As regards MT$_2$ receptors, the synthetic MT$_2$ agonist (UCM765) has been reported to mimic the anxiolytic properties of MT$_1$ and its actions were blocked by a selective MT$_2$ receptor antagonist.102 In line with this work, male and/or female mice genetically deprived of MT$_2$ receptors display enhanced anxiety.105–108 As regards human subjects, data are very sparse, yet there is fragmentary evidence for anxiolytic effects of MT under specific conditions, such as pre-operative stress.100,109

Independently of any direct influence of MT agonism on circuits mediating and controlling anxiety, MT receptor stimulation by agomelatine should be linked to an improvement (advanced onset) of sleep and circadian rhythms.110,111 Since sleep is commonly perturbed in patients with GAD, this would be expected to favour the relief of anxious states.5,7,35

Comparatively, few studies have to date been undertaken with agomelatine to specifically identify its anxiolytic loci of action in the brain. One pragmatic reason for this is the highly lipophilic nature of agomelatine, leading to rapid diffusion through neural tissue: this renders intracerebral microinjection studies problematic. Nonetheless, a functional magnetic resonance imaging (fMRI) study in rats found that agomelatine blocked the ‘BOLD’ response to a selective 5-HT$_{2C}$ agonist (RO-60,0175) in the mediodorsal thalamus as well as the cortex, ventral hippocampus and periaqueductal grey,112 key structures involved in the processing of fear and anxiety in animals and humans.6,35,113,114 These findings support a role for 5-HT$_{2C}$ receptors in the hippocampus in the anxiolytic actions of agomelatine. Interestingly, systemic administration of agomelatine exerts a marked influence on synaptic plasticity, diverse intracellular signals, and neuromodulators like neural cell adhesion molecule, an emotion-regulating growth factor, in this structure.23,115,116

Findings with selective 5-HT$_{2C}$ receptor agonists and antagonists underscore a role of the hippocampus in the modulation of anxiety, and they also provide evidence for roles of 5-HT$_{2C}$ receptors in the amygdala (basolateral and central nuclei) and the interconnected bed nucleus of the stria terminalis (BNST). For example, activation of 5-HT$_{2C}$ receptors in the basolateral amygdala underlies the induction of anxiety by stimulation of the raphe nucleus.117 These regions comprise core elements of a stress-sensitive, fear-integrating circuit involved in the induction of anxious states that is modulated by 5-HT$_{2C}$ receptors and, ipso facto, one may assume agomelatine (see also next section).

Like 5-HT$_{2C}$ receptors, both MT$_1$ and MT$_2$ receptors are localized in the hippocampus (mainly dentate gyrus and CA3 regions, respectively). The former are also highly concentrated in the SCN,
whereas the latter are prominent in the thalamic reticular nucleus (TRN). As mentioned above, the approach of discrete brain lesions suggests that the integrity of the MT1 receptor-enriched SCN, the circadian master regulator, is required for alleviation by agomelatine of anxious behaviour following social defeat. Agomelatine interacts with circadian-rhythm-related genes (like ‘Period-1’) in the SCN (and hippocampus): studies are undergoing to determine if and how this influence relates to specific classes of anxiety disorders. On the contrary, the above-mentioned MT2 receptor agonist UCM765 activates neurons in the TRN that via the dorsal medial thalamus to the frontal cortex (FCX), which itself feeds into the amygdala-BNST axis to control anxious states. Accordingly, it has been proposed that activation of MT2 receptors in the TRN acts via this neural cascade to counter anxiety, and they are a potential substrate for the anxiolytic actions of agomelatine. This possibility is especially interesting bearing in mind the role of the TRN in sleep and evidence that agomelatine influences the activity of neurons in the dorsomedial thalamus and FCX downstream of the TRN. Finally, a role of either MT1 and/or MT2 receptors in the hippocampus may, by analogy to their 5-HT2C counterparts, be involved in the response to stress and the anxiolytic actions of MT together with, by extrapolation, agomelatine.

**Potential neurochemical substrates of action involved in the anxiolytic actions of agomelatine**

As regards neurochemical substrates involved in the anxiolytic properties of agomelatine, it is interesting to consider potential roles for glutamate and several different classes of neuropeptide. Both 5-HT2C receptor ligands and SSRIs have been found to impact stress-sensitive glutamatergic transmission in structures like the FCX, hippocampus, and amygdala. As regards agomelatine itself, its acute administration blunted stress-induced release of glutamate in the basolateral and central amygdala as well as the hippocampus. In the past, the tendency has been to automatically relate this modulation of glutamatergic pathways (and other neurochemical effects of agomelatine) to its antidepressant actions. However, these effects might more compellingly be interlinked with its anxiolytic properties in view of the pivotal role of the amygdala and hippocampus in the regulation of fear and anxiety.
Modulation of the activity of the anxiogenic peptide, corticotrophin-releasing factor (CRF) in the amygdala and the BNST has been implicated in the influence of 5-HT receptors – and, by extension, agomelatine – upon anxious states. Of particular interest, serotonergic pathways projecting to the BNST from the dorsal raphe act via 5-HT receptors to engage a CRF circuit that inhibits the anxiolytic influence of a BNST projection to the lateral hypothalamus and ventromedial area. Activation of these 5-HT receptors by SSRIs is thought to underlie their anxiolytic and antidepressant effects. Agomelatine would act oppositely to SSRIs in blocking BNST-located 5-HT sites and moderating CRF output, contributing to the expression of its anxiolytic properties in the absence of an early phase of aggravated anxiety. CRF may not be the only neuropeptide potentially implicated in the actions of agomelatine. Post-weaning isolation in rats is associated with heightened anxiety in adults, together with reduced plasma levels of oxytocin (which possesses anxiolytic properties) and elevated levels of vasopressin (‘anxiogenic’). Sub-chronic (2 weeks) administration of agomelatine moderated anxiety as well as reversing the increases in vasopressin levels, and (albeit only in females) it also attenuated the fall in levels of oxytocin. These effects were specific since, despite the above-described influence on CRF in the BNST, there was no apparent influence on corticosterone levels downstream of the hypothalamic–pituitary–adrenal axis. Intriguingly, there is evidence that 5-HT receptors physically associate with and blunt signalling at oxytocin receptors and that oxytocin hypoactivity is countered by 5-HT antagonists including, at least in theory, agomelatine.

Serotonergic projections are subject to the inhibitory control of GABAergic interneurons expressed both at the level of terminals and of cell bodies in raphe nuclei. Accordingly, benzodiazepines suppress (‘excess’) release of 5-HT by activation of GABA-A receptors presynaptic to serotonergic neurons in the dorsal raphe nucleus, hippocampus, amygdala, and other regions, actions that contribute to their anxiolytic properties. Interestingly, at least in rodents, 5-HT receptors are expressed by raphe-localized GABAergic interneurons targeting serotonergic pathways projecting to the basolateral amygdala. Under conditions of acute stress, 5-HT agonists attenuate the activity of ascending serotonergic pathways. This action, and some – albeit inconsistent – evidence for anxiolytic properties of 5-HT agonists, likely reflect recruitment of GABAergic interneurons upstream of serotonergic pathways. Nonetheless, presumably reflecting the low tonic activity of 5-HT receptors on GABAergic neurons, as assessed by dialysis in freely moving rats and at anxiolytic doses, agomelatine did not modify extracellular levels of 5-HT in the hippocampus or other structures (Figure 3). This lack of impact on extracellular levels of 5-HT mimics selective 5-HT antagonists and distinguishes agomelatine both to benzodiazepines (decreased release of 5-HT) and to SSRIs and SNRIs which elevate synaptic levels of 5-HT by blocking 5-HT reuptake sites on serotonergic terminals: increases are seen both acutely and upon long-term administration. Agomelatine may also be contrasted in this respect to buspirone, which decreases extracellular levels of 5-HT in corticolimbic territories by recruitment of 5-HT autoreceptors on raphe cell bodies. In contrast to other classes of anxiolytic, then, agomelatine exerts its anxiolytic properties in the apparent absence of alterations in the release of 5-HT.

**Relationship of the anxiolytic properties of agomelatine to its antidepressant actions**

Blockade of 5-HT receptors and activation of MT receptors are the core mechanisms of action harnessed by agomelatine both in the treatment of GAD and, as amply discussed elsewhere, in the management of major depression. Clearly, then, the anxiolytic and antidepressant actions of agomelatine are fully compatible, and they are expressed over similar dose-ranges in patients with GAD and major depression, respectively. Under conditions of comorbid GAD and depression, antidepressant and anxiolytic properties may mutually reinforce each other. Interestingly, furthermore, relief of anxious states may help hinder the course to major depression. Although formal trials remain to be performed, these elements, combined with the ability of agomelatine to counteract the anxiety associated with chronic stress in rats (vide supra), suggest that it should relieve ‘mixed’ anxiodepressive conditions in patients. Noting interconnections between the anxiolytic and antidepressant actions of agomelatine is not, however, to contend that the same populations of 5-HT and MT receptors and the same downstream substrates are implicated. Indeed, the above-discussed neural mechanisms engaged by agomelatine in the relief of anxious states are unlikely to mediate its impact on major depression.
Conversely, pivotal to the antidepressant actions of agomelatine is its enhancement of the activity of dopaminergic and adrenergic pathways projecting to the FCX. This effect is unrelated to the anxiolytic properties of agomelatine, despite a possible role for 5-HT$_{2C}$ receptors in the FCX – interconnected with the amygdala–BNST.\textsuperscript{35,113,142,143}

**General discussion: open questions and perspectives**

Finally, additional study should provide further insights into the mechanisms of action of agomelatine in the treatment of GAD.

First, at the cellular level, by analogy to 5-HT$_{2C}$ receptor-Oxytocin receptor heterodimers (vide supra), a physical interaction between 5-HT$_{2C}$ and MT$_2$ receptors has been demonstrated both in cellular expression systems, as well as the hippocampus and cortex of rats.\textsuperscript{144,145} 5-HT$_{2C}$-MT$_2$ functional heterodimers possess ligand recognition and coupling properties that differ from the constituent monomers and dimers. Since agomelatine potently recognizes these heterodimers, it has been speculated that they may be involved in the clinical actions of agomelatine in depression. The same might be contended for GAD. However, while there is increasing evidence for the relevance of heteromeric G-protein-coupled receptor (GPCR) complexes to central nervous system (CNS) disorders,\textsuperscript{146,147} it is not yet known whether 5-HT$_{2C}$-MT$_2$ heterodimers are affected in the brain of GAD patients, nor whether their activity is altered under conditions of stress. Furthermore, ligands highly selective for 5-HT$_{2C}$-MT$_2$ heterodimers versus constituent monomers would be needed to rigorously evaluate their functional significance. Such agents are being sought but have not yet been described.\textsuperscript{145}

Second, at the neurochemical and network level, it would be interesting to determine whether other neuromediators interlinked with 5-HT$_{2C}$ receptors and known to influence anxious states, like cannabinoids and Neuropeptide Y, are involved in the actions of agomelatine.\textsuperscript{148–150} Furthermore, induction of brain-derived neurotrophic factor (and neurogenesis) in the hippocampus and FCX has been related to the antidepressant actions of agomelatine – and many other antidepressants – and it may be more generally involved in the response to stress and anxious states.\textsuperscript{53,115,150–152} Interestingly, 5-HT$_{2C}$ receptor knockout mice reveal increased expression of brain-derived neurotrophic factor in the hippocampus.\textsuperscript{153} It would also be insightful to acquire a clearer picture of the neural structures where agomelatine exerts its actions, exploiting both animal models and human subjects. In addition to the amygdala–BNST, the hippocampus and the FCX (Figure 2), other structures warrant investigation such as the GAD-implicated habenula.\textsuperscript{3} In this MT receptor–rich structure,\textsuperscript{123} 5-HT$_{2C}$ receptors play a role in the control of anxiety,\textsuperscript{122,154,155} 5-HT$_{2C}$ receptors localized in the dorsal striatum also participate in the induction of anxious states.\textsuperscript{118,156} A final structure worth citing that possesses both MT receptors and 5-HT$_{2C}$ receptors is the periaqueductal grey: this midbrain region is involved in the triggering of anxiety and has been identified as a site of action of 5-HT$_{2C}$ antagonists.\textsuperscript{6,122,157,158} In addition to animal studies, clarification of neural circuits involved in the anxiolytic actions of agomelatine could be attempted in human subjects. This enterprise is however complicated – notwithstanding the sustained efforts of many laboratories – by the lack of specific positron emission tomography (PET)-imaging ligands.\textsuperscript{159} An alternative approach, highlighted by work in rodents, would be fMRI and electroencephalographic strategies for exploring circuits involved in the relief of GAD by agomelatine in comparison to other classes of agent.\textsuperscript{85,108,112,160}

Third, the anxiolytic effects of agomelatine are expressed principally via 5-HT$_{2C}$ receptors and ‘directly’ in interaction with corticolimbic and other subcortical circuits controlling anxious states. Nonetheless, in a clinical context, a beneficial influence of agomelatine on sleep patterns quality and circadian rhythms would be helpful in the relief of GAD and the improvement of quality of life. The influence of agomelatine upon sleep onset and rhythms is mainly melatonergic (MT receptor stimulation) in nature,\textsuperscript{161–163} but a contribution of 5-HT$_{2C}$ receptor blockade should not be neglected.\textsuperscript{85,110,111,164} In fact, blockade of 5-HT$_{2C}$ receptors likely contributes to the short-term improvement by antidepressants like trazodone and mirtazapine of sleep, although their sedative properties – due to histamine H$_1$ antagonism – become problematic in some patients.\textsuperscript{48,165,166} Conversely, an influence upon sleep of agomelatine (which possesses neither affinity for H$_1$ receptors nor marked sedative properties) does not play a major role in its antidepressant properties.\textsuperscript{22,110,165,166} Hence, to answer the question of whether – and by which mechanisms – a positive influence of agomelatine upon sleep and daily cycles putatively contributes to its relief of GAD, dedicated studies in patients will be required.\textsuperscript{22,28,165,167}
Fourth, since agomelatine has only been evaluated in adult populations for the relief of GAD, it would be of interest to examine its potentially beneficial influence on GAD in specific populations like the young, including children and adolescents. Finally, in view of positive results in tests of social interaction in rodents and the social dimension of GAD, clinical studies of Social Anxiety Disorder and specific types of social phobia would be of interest.

Finally, agomelatine is currently the only clinically authorized compound to possess a co-joint 5-HT2C receptor antagonist plus MT1/MT2 agonist profile. Nonetheless, at least one new agent (GW117) with a comparable binding profile has recently been documented. Furthermore, it would be interesting to explore complementary ‘multi-target’ classes of agent articulated around 5-HT2C receptor antagonist and/or MT agonist profiles for their potential utility in the improved treatment of GAD and other classes of anxiety disorder.

Concluding comments
In conclusion, agomelatine expresses its therapeutic efficacy in GAD principally via its antagonist properties at 5-HT2C receptors with MT1/MT2 agonism providing complementary anxiolytic properties. Its actions at these receptors are distributed across several brain structures like the hippocampus, amygdala-BNST, SCN, and TRN, and they are expressed in interaction with a suite of neurotransmitters and neuropeptides like glutamate, CRF, and vasopressin, but the precise underlying substrates await further clarification. Agomelatine displays a novel and fundamentally different mechanism of anxiolytic action as compared to all other classes of medication used to treat GAD, accounting for its clinical efficacy in the relative absence of deleterious actions.

Author contribution(s)
Mark J. Millan: Conceptualization; Formal analysis; Investigation; Writing – original draft; Writing – review & editing.

ORCID iD
Mark J. Millan https://orcid.org/0000-0002-6253-0301

Acknowledgements
The author would like to thank Brian Morris and Kevin Fone for helpful comments on the manuscript and Jean-Michel Rivet for help in the preparation of the figures.

Funding
The author received no financial support for the research, authorship, and/or publication of this article.

Conflict of interest statement
The author declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The author was until 2020 an employee of Institute de recherche Servier and participated in the discovery, characterization, and development of agomelatine for the treatment both of major depression and GAD. This review was written upon invitation by the Institute International de recherche de Servier, from whom the author received financial compensation.

Supplemental material
Supplemental material for this article is available online.

References


81. Millan MJ, Girardon S and Dekeyne A. 5-HT2C receptors are involved in the


100. Huang F, Yang Z and Li CQ. The melatonergic system in anxiety disorders and the role of melatonin in conditional fear. *Vitam Horm* 2017; 103: 281–294.


105. Liu J, Clough SJ and Dubocovich ML. Role of the MT(1) and MT(2) melatonin receptors in mediating depressive- and anxiety-like behaviors in C3H/HeN mice. Genes Brain Behav 2020; 19: e12653.


